We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Rank # 2 (Buy) rated Amgen’s strong Q2 earnings report earlier this week - it beat on the top- and bottom-lines and guided higher - has helped the stock's positive momentum in recent weeks that followed a weak start earlier. The stock has gained in excess of 12% over the last four weeks, bringing it's year-to-date performance about in-line with the broader market. The analyst likes the company’s cost cutting initiatives, share buybacks and strong performance of key products. Amgen’s pipeline is also progressing well with quite a few regulatory and data updates scheduled for the coming quarters.(You can read the full research report on AMGN here.)
J.P. Morgan shares are down on the year, but they have gained some ground lately, particularly following the Q2 earnings report. The banking giant not only beat expectations, but also reiterated their outlook for the rest of the rest of the year despite a variety of new headwinds. Improvement in trading revenue, rise in mortgage banking fees and higher net interest income supported top line growth. The analyst likes the synergies gained from improving retail banking performance and cost-containment efforts, which will help the company improve its profitability. Further, approval of its 2016 capital plan is indicative of a strong balance sheet.(You can read the full research report on JPM here.)
Mondelez beat the Zacks Consensus Estimate for earnings, but missed on revenues in the second-quarter report that added worries about the company's exposure to an uncertain macro environment in emerging markets. These near-term headwinds notwithstanding, the analyst likes the fact that margins have remained consistently strong backed by cost savings and productivity gains. Additionally, the company is refreshing its brand portfolio through product innovation and extending its brands to newer geographies and platforms. Mondelez is keen on expanding its business through acquisitions and has been regularly divesting non-core underperforming businesses (You can read the full research report on MDLZ here.)
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles includeEarnings TrendsandEarnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.
If you want an email notification each time Sheraz publishes a new article, pleaseclick here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top 7 Research Reports for July 29, 2016
Friday, July 29, 2016
Today's must-read reports are for Amgen (AMGN - Free Report) , JPMorgan (JPM - Free Report) and Mondelez (MDLZ - Free Report) .
Zacks Rank # 2 (Buy) rated Amgen’s strong Q2 earnings report earlier this week - it beat on the top- and bottom-lines and guided higher - has helped the stock's positive momentum in recent weeks that followed a weak start earlier. The stock has gained in excess of 12% over the last four weeks, bringing it's year-to-date performance about in-line with the broader market. The analyst likes the company’s cost cutting initiatives, share buybacks and strong performance of key products. Amgen’s pipeline is also progressing well with quite a few regulatory and data updates scheduled for the coming quarters.(You can read the full research report on AMGN here.)
J.P. Morgan shares are down on the year, but they have gained some ground lately, particularly following the Q2 earnings report. The banking giant not only beat expectations, but also reiterated their outlook for the rest of the rest of the year despite a variety of new headwinds. Improvement in trading revenue, rise in mortgage banking fees and higher net interest income supported top line growth. The analyst likes the synergies gained from improving retail banking performance and cost-containment efforts, which will help the company improve its profitability. Further, approval of its 2016 capital plan is indicative of a strong balance sheet.(You can read the full research report on JPM here.)
Mondelez beat the Zacks Consensus Estimate for earnings, but missed on revenues in the second-quarter report that added worries about the company's exposure to an uncertain macro environment in emerging markets. These near-term headwinds notwithstanding, the analyst likes the fact that margins have remained consistently strong backed by cost savings and productivity gains. Additionally, the company is refreshing its brand portfolio through product innovation and extending its brands to newer geographies and platforms. Mondelez is keen on expanding its business through acquisitions and has been regularly divesting non-core underperforming businesses (You can read the full research report on MDLZ here.)
Other noteworthy reports we are featuring today include Oracle (ORCL - Free Report) , Thermo Fisher (TMO - Free Report) and Toyota (TM - Free Report) .
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.
If you want an email notification each time Sheraz publishes a new article, please click here.